Bausch + Lomb (BLCO) vs RxSight (RXST)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Bausch + Lomb (BLCO) has outperformed RxSight (RXST) over the past year, gaining 28.6% versus a loss of 56.0%. Bausch + Lomb is the larger company by market cap ($6.93 billion vs $187.4 million), about 37.0 times the size. Bausch + Lomb converts more of its revenue into profit, with a net margin of -7.1% versus -29.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BLCO | RXST |
|---|---|---|
| Share price | $19.38 | $4.47 |
| Market cap | $6.93B | $187.42M |
| 1-day change | -6.33% | -3.04% |
| YTD return | +13.47% | -57.10% |
| 1-year return | +28.60% | -55.96% |
| 5-year return | — | -63.86% |
| Forward P/E | 16.36 | — |
| EPS (TTM) | $-0.32 | $-1.29 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $5.10B | $134.48M |
| Revenue growth (YoY) | +6.47% | -3.89% |
| Net income (latest FY) | $-360.00M | $-38.94M |
| Gross margin | — | 76.60% |
| Operating margin | 2.22% | -35.84% |
| Net margin | -7.06% | -28.96% |
| 52-week high | $21.40 | $13.22 |
| 52-week low | $14.65 | $4.11 |
| Distance from 52-week high | -9.44% | -66.19% |
| Analyst consensus | buy | hold |
| Avg. price target upside | +13.16% | +36.47% |
| Average volume | 660.67K | 826.96K |
| Shares outstanding | 357.50M | 41.93M |
| Employees | 13,000 | 461 |
| Sector | Health Care | Health Care |
| Industry | Ophthalmic Goods | Ophthalmic Goods |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Bausch + Lomb is about 37.0 times larger than RxSight by market value ($6.93B vs $187.42M).
- BLCO has outperformed RXST by 84.6 percentage points over the past year.
- Bausch + Lomb is more profitable, keeping -7.1 cents of every revenue dollar as net income versus -29.0 cents for RxSight.
- Bausch + Lomb grew revenue faster in its latest fiscal year (+6.47% vs -3.89%).
About Bausch + Lomb
BLCO stock →Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical.
Health Care · Ophthalmic Goods · 13,000 employees
About RxSight
RXST stock →RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.
Health Care · Ophthalmic Goods · 461 employees
BLCO vs RXST FAQ
Which is bigger, Bausch + Lomb or RxSight?
Bausch + Lomb (BLCO) is larger, with a market capitalization of $6.93B compared with $187.42M for RxSight (RXST).
Which stock has performed better over the past year, BLCO or RXST?
BLCO returned +28.60% over the past 12 months, compared with -55.96% for RXST (price return, excluding dividends). Past performance does not predict future results.
Are Bausch + Lomb and RxSight in the same industry?
Yes. Both are classified in the Ophthalmic Goods industry within the Health Care sector.